Drug Trial Radar · NCT07557446
A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Jul 14, 2026
Primary completion
Apr 2028
Study completion Jul 2029
Sponsor
- Lead sponsor
- Angitia Biopharmaceuticals Guangzhou LimitedIndustry
- Sponsor type
- Industry
- First posted
- Apr 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the safety and efficacy of AGA2115 at three different dose regimens in Chinese adults and adolescents with Type I, III, or IV Osteogenesis imperfecta (OI).
Conditions
- Osteogenesis Imperfecta (OI)
Interventions
AGA2115Drug
Participants will receive AGA2115 administered by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Baseline to Month 27 (Cohorts 1 and 5); Baseline to Month 24 (Cohorts 2, 3, 4, 6, 7 and 8)
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Chinese Academy of Medical Sciences, Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Recruiting
The University of Hong Kong-Shenzhen Hospital
Shenzhen, Guangdong, China · Recruiting
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China · Not yet recruiting
Children's Hospital of Soochow University
Suzhou, Jiangsu, China · Not yet recruiting
Shanghai Sixth People's Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.